Case report: Acute pancreatitis in lung adenocarcinoma with small cell transformation after multiple line targeted therapy

Yaoyao Jing, Xiaoxiao Li, Xiaoyuan Sun, Minghan Ren, Ruoxi Xiao, Jiayu Zhao, Zimin LiuFrontiers in Oncology 2024 · DOI

TL;DR

This case report documents a rare clinical phenomenon where a patient’s lung adenocarcinoma (LUAD) transformed into small cell lung cancer (SCLC) as a resistance mechanism to long-term targeted therapy. This "lineage switching" led to an unusual metastatic site—the pancreas—which manifested clinically as acute pancreatitis, highlighting the need for vigilance in patients with treatment-resistant lung cancer.

What Problem Does This Paper Address?

In the era of precision medicine, patients with non-small cell lung cancer (NSCLC) harboring specific mutations (like EGFR) often receive targeted therapies called Tyrosine Kinase Inhibitors (TKIs). While initially effective, the cancer almost inevitably develops resistance. One of the most challenging resistance mechanisms is phenotypic transformation, where the cancer cells physically change from adenocarcinoma to small cell carcinoma.

This paper addresses two major clinical hurdles:

  1. Diagnostic Complexity: Identifying when a lineage shift has occurred, especially when the cancer spreads to uncommon sites.
  2. Rare Manifestations: Pancreatic metastasis from lung cancer is rare (occurring in roughly 0.25% of cases). When it does occur, it can trigger Metastasis-Induced Acute Pancreatitis (MIAP), a condition that can easily be misdiagnosed as primary pancreatitis, delaying life-saving oncology interventions.

Methods

As a clinical case report, the "methods" involve a longitudinal diagnostic workup of a single patient over an eight-year period. Key techniques used include:

  • Sequential Genetic Testing: The authors used Next-Generation Sequencing (NGS) at multiple stages of disease progression to track the evolution of mutations (e.g., EGFR L858R, T790M, and eventually TP53 and MET).
  • Multimodal Imaging: Utilization of PET-CT, enhanced CT, and MRI to identify metastatic lesions and monitor the inflammatory state of the pancreas.
  • Histopathology and Immunohistochemistry (IHC): To confirm the SCLC transformation, the team performed ultrasound-guided biopsies of the pancreatic mass. They tested for specific markers including CK, CD56, Synaptophysin (Syn), TTF-1, and Ki67.

Datasets

As this is a Case Report, there is no large-scale dataset or training set. However, the authors reference retrospective data from the Peking Union Medical College Hospital (analyzing 17,045 patients) to provide context on the rarity of pancreatic metastasis.

Key Insights and Ideas

  • Lineage Plasticity as Resistance: The case reinforces the theory that LUAD and SCLC may share a common cellular origin (alveolar type II cells). Under the "selective pressure" of long-term TKI therapy (in this case, erlotinib and osimertinib), the cancer cells may switch lineages to survive.
  • The "Red Flag" of Pancreatitis: In an older patient with a history of lung cancer, unexplained acute pancreatitis should be treated as a potential sign of metastatic progression rather than just a digestive issue.
  • Molecular Predictors: The authors note that the loss or mutation of TP53 and RB1 are often precursors to SCLC transformation. In this patient, the emergence of a TP53 mutation preceded the clinical detection of the SCLC phenotype.
  • Treatment Pivot: Once transformation is confirmed, the treatment paradigm must shift entirely. Targeted therapies for NSCLC are typically ineffective against the transformed SCLC component, requiring a switch to traditional platinum-based chemotherapy (etoposide and cisplatin).

Key Results

  • Pathological Confirmation: Biopsy of the pancreatic head revealed small cell carcinoma that tested positive for neuroendocrine markers (CD56, Syn), confirming it originated from the transformed lung primary.
  • Biomarker Correlation: The patient showed significantly elevated levels of pro-gastrin-releasing peptide (pro-GRP), a specific tumor marker for SCLC, which correlated with the pancreatic involvement.
  • Clinical Outcome: After switching to an SCLC-specific chemotherapy regimen (etoposide + cisplatin), the pancreatic masses shrunken, and the pancreatitis resolved. However, the aggressive nature of transformed SCLC was evident as the patient developed brain metastases and passed away seven months after the pancreatic diagnosis.

Limitations and Future Work

The primary limitation is that this is a single-patient observation. While it provides a detailed roadmap of a rare event, it cannot establish a universal frequency for these occurrences.

The authors suggest that future research should focus on:

  • Standardizing Diagnostic Criteria: Developing clearer protocols for when to biopsy new lesions in TKI-resistant patients to catch lineage transformations earlier.
  • Novel Therapeutic Strategies: Since transformed SCLC is highly aggressive and often resistant to standard therapies, there is a dire need for new drugs targeting the molecular drivers of this specific transformation.
  • Surveillance: Investigating whether routine monitoring of serum pro-GRP could serve as an early warning system for SCLC transformation in NSCLC patients.

Summary updated

Abstract

In lung cancer, metastasis to the liver, bones, brain, and adrenal glands is more commonly observed, whereas pancreatic metastasis from lung cancer is relatively rare. We present a case of a patient with an 8-year history of lung adenocarcinoma (LUAD) who was admitted to our institution exhibiting symptoms consistent with acute pancreatitis. Subsequent histopathological examination through puncture confirmed the occurrence of pancreatic metastasis originating from small cell lung cancer (SCLC). During a multidisciplinary team discussion, we reached a consensus in diagnosing the patient with post-transformation small cell carcinoma alongside moderately severe pancreatitis, which was determined to be a consequence of pancreatic metastasis. The patient received a regimen of etoposide and cisplatin chemotherapy. This unique clinical case highlights the importance of further investigating the factors contributing to pancreatic metastasis in patients with lung cancer, as the underlying mechanisms remain unclear. Understanding these exceptional metastatic events is vital in devising effective therapeutic strategies and improving patient prognosis. Our findings emphasize the need for continued surveillance and comprehensive management of lung cancer patients, particularly those with resistant forms of the disease, to promptly identify and address the progression of metastatic events to uncommon sites such as the pancreas.
BibTeX
@inproceedings{jing2024case,
  author = {Yaoyao Jing and Xiaoxiao Li and Xiaoyuan Sun and Minghan Ren and Ruoxi Xiao and Jiayu Zhao and Zimin Liu},
  title = {{Case report: Acute pancreatitis in lung adenocarcinoma with small cell transformation after multiple line targeted therapy}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1274034},
}
Figure